Key result
Glimepiride produced similar decreases in fasting plasma glucose and HbA1C compared to glyburide, but with a lower incidence of hypoglycemia.
Why the study?
Does glimepiride improve glycemic control (fasting plasma glucose and HbA1C) compared to glyburide in patients with NIDDM?
RCT (n=577)
Double-blind
parallel-group
Yes
Does glimepiride improve glycemic control (fasting plasma glucose and HbA1C) compared to glyburide in patients with NIDDM?
Glimepiride provides similar glycemic control to glyburide in NIDDM patients but with a lower risk of hypoglycemia.
Answers are grounded in this paper and cite their sources.
Supports preferring glimepiride to minimize hypoglycemia in NIDDM; confirms comparable efficacy with a safer profile versus glyburide.
We report on the results of a one-year, multicenter, randomized, double-blind, parallel-group titration study of the new sulfonylurea agent, glimepiride, versus use of non-micronized glyburide to treat 577 patients with non-insulin dependent diabetes mellitus (NIDDM). Similar decreases in both fasting plasma glucose and HbA1C were found using glimepiride and glyburide. There was a lower incidence of hypoglycemia with glimepiride than glyburide.
No takes yet. Share an insight, caveat, or question.
Dills et al. (1996) conducted an RCT in non-insulin dependent diabetes mellitus (NIDDM) (n=577). Glimepiride vs. Non-micronized glyburide was evaluated on Fasting plasma glucose and HbA1C. Glimepiride produced similar decreases in fasting plasma glucose and HbA1C compared to glyburide, but with a lower incidence of hypoglycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: